ストックスクリーナーアプリを入手
7.45
9.08%
0.62
プレマーケット:
7.51
0.06
+0.81%
前日終値:
$6.83
開ける：
$7.22
24時間の取引高:
10.95M
Relative Volume:
0.88
時価総額：
$7.80B
収益：
$140.98M
当期純損益:
$-854.60M
株価収益率:
-8.7237
EPS:
-0.854
ネットキャッシュフロー:
$-299.31M
1週間 パフォーマンス:
+0.68%
1か月 パフォーマンス:
-15.05%
6か月 パフォーマンス:
+19.20%
1年 パフォーマンス:
+191.02%
1日の値動き範囲:
$7.00
$7.47
1週間の範囲:
$6.65
$7.47
52週間の値動き範囲:
$1.95
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Compare IBRX vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
7.45 | 7.32B | 140.98M | -854.60M | -299.31M | -0.854 |
VRTX
Vertex Pharmaceuticals Inc
|
481.70 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
738.34 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
872.58 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
192.17 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
322.08 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-12 | 再開されました | BTIG Research | Buy |
| 2025-05-20 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | 開始されました | H.C. Wainwright | Buy |
| 2025-01-10 | 開始されました | BTIG Research | Buy |
| 2023-05-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | 開始されました | Jefferies | Buy |
すべてを表示
Immunitybio Inc (IBRX) 最新ニュース
ImmunityBio, Inc. (IBRX) Investigation: Bronstein, Gewirtz & Gros - The National Law Review
IBRX|Immunitybio Inc|Price:7.000|Chg%:-0.100 - TradingKey
IBRX Stock In Spotlight: ImmunityBio To Unveil Fresh Anktiva And BCG Data Next Week - Stocktwits
IBRX Stock Climbs Overnight: ImmunityBio Declares ‘All Systems Go’ For Dunkirk Anktiva Manufacturing Push - Stocktwits
PATRICK SOON-SHIONG - Orange County Business Journal
Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IBRX) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
IBRX Stock Rises Overnight: Retail Traders Hunt For Global Expansion Clues Ahead Of Biotech Conference - Yahoo Finance
Immunitybio Inc (IBRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ImmunityBio Founder Pushes Back After FDA Warning Letter Over Anktiva Claims — Says Ad 'Never Aired At All' - Stocktwits
Immunitybio Inc (IBRX) Institutional Confidence - TradingKey
Immunitybio Inc (IBRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Immunitybio Inc (IBRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio, Inc. (IBRX) And Encourages Shareholders to Connect - ACCESS Newswire
IBRX Stock Eyes Best Week Since February: Founder Highlights New Anktiva-NK Cell Therapy Study - Stocktwits
Immunitybio Inc (IBRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ImmunityBio, Inc. (IBRX) And Encourages Shareholders to Reach Out - ACCESS Newswire
ImmunityBio: Revisiting My Bearish Call After A Strong Rally (Rating Upgrade) - Seeking Alpha
ImmunityBio (NASDAQ:IBRX) stock faces July 24 warrant-expiry test after Friday rebound - TechStock²
ImmunityBio (IBRX) Could Be 41% Below Fair Value After Anktiva Optimism - Sahm
ImmunityBio: ANKTIVA's Commercial Momentum Supports A Buy (NASDAQ:IBRX) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ImmunityBio, Inc. (IBRX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
ImmunityBio (IBRX) Could Be 41% Undervalued On Anktiva Optimism - Yahoo Finance
ImmunityBio: Intriguing Progress, If Not (Yet) CommerciallyStill A Hold (NASDAQ:IBRX) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio - The National Law Review
Are Surging IBRX Retail Debates Hinting at a Deeper Re‑rating of ImmunityBio’s Platform? - Sahm
ImmunityBio, Inc. (IBRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio, Inc. (IMMP) And Encourages Investors to Connect - The National Law Review
IBRX Stock Climbs Premarket Despite Investor Stake Cut — Retail Sees ‘Imminent’ Global Rollout Catalyst - TradingView
IBRX Stock In Spotlight As FDA Scrutiny Prompts ImmunityBio To Withdraw Content, Tighten Oversight - Stocktwits
Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio, Inc. (IBRX) And Encourages Investors to Connect - ACCESS Newswire
ImmunityBio (IBRX) Could Be 37% Below Fair Value Following Revenue Surprise Talk - Sahm
IBRX Stock Slips Overnight: Insider Sale Tests Retail Optimism Ahead Of FDA Growth Catalyst - Stocktwits
ImmunityBio Stock Short Interest Falls to 33.94% - Quiver Quantitative
IBRX Stock Surges Past 4-Year Highs: Analyst Sees over 50% Upside After Anktiva’s Blowout Growth - Stocktwits
ImmunityBio Founder Reaffirms Grip As Stock Plunges In Worst Selloff Since 2024 After Massive Rally - Stocktwits
IBRX Stock Steadies As Director Cheryl Cohen Unloads Shares - StocksToTrade
ImmunityBio : IBRX - 24/7 Wall St.
Can IBRX Stock Keep Its Pulse? Institutional Investors Buy In, Retail Hopes For Big Q2 Surprise - TradingView
Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IBRX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
IBRX Stock Still A Buy After Worst Day In Over A Year? Why This Analyst Is Shrugging Off FDA Warning Letter - Stocktwits
IBRX Stock Down 10% This Week, But Its CEO Just Outlined 3 Reasons Bull Case Is Intact - Stocktwits
IBRX Stock Rises Premarket: Anktiva Moves Into Pre-Surgery Pancreatic Cancer Combo Trial With Bristol Myers Drug - Stocktwits
Immunitybio Inc (IBRX) 財務データ
収益
当期純利益
現金流量
EPS
Immunitybio Inc (IBRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Cohen Cheryl | Director |
Jul 02 '26 |
Sale |
9.50 |
131,210 |
1,246,941 |
125,386 |
| Selecky Christobel | Director |
Jul 01 '26 |
Option Exercise |
2.99 |
159,478 |
476,489 |
159,478 |
| Selecky Christobel | Director |
Jul 01 '26 |
Sale |
9.02 |
159,478 |
1,439,066 |
0 |
0.11%
5.02%
大文字化:
|
ボリューム (24 時間):